Ground-based gamma-ray astronomy has had a major breakthrough with the impressive results obtained using systems of imaging atmospheric Cherenkov telescopes. Ground-based gamma-ray astronomy has a huge potential in astrophysics, particle physics and cosmology. CTA is an international initiative to build the next generation instrument, with a factor of 5-10 improvement in sensitivity in the 100 GeV-10 TeV range and the extension to energies well below 100 GeV and above 100 TeV. CTA will consist of two arrays (one in the north, one in the south) for full sky coverage and will be operated as open observatory. The design of CTA is based on currently available technology. This document reports on the status and presents the major design concepts of CTA.

The Cherenkov Telescope Array (CTA) is a new observatory for very high-energy (VHE) gamma rays. CTA has ambitions science goals, for which it is necessary to achieve full-sky coverage, to improve the sensitivity by about an order of magnitude, to span about four decades of energy, from a few tens of GeV to above 100 TeV with enhanced angular and energy resolutions over existing VHE gamma-ray observatories. An international collaboration has formed with more than 1000 members from 27 countries in Europe, Asia, Africa and North and South America. In 2010 the CTA Consortium completed a Design Study and started a three-year Preparatory Phase which leads to production readiness of CTA in 2014. In this paper we introduce the science goals and the concept of CTA, and provide an overview of the project. ?? 2013 Elsevier B.V. All rights reserved

Clinically relevant intensity modulated proton therapy (IMPT) treatment plans were measured in a newly developed anthropomorphic phantom (i) to assess plan accuracy in the presence of high heterogeneity and (ii) to measure plan robustness in the case of treatment uncertainties (range and spatial). The new phantom consists of five different tissue substitute materials simulating different tissue types and was cut into sagittal planes so as to facilitate the verification of co-planar proton fields. GafChromic films were positioned in the different planes of the phantom, and 3D-IMPT and distal edge tracking (DET) plans were delivered to a volume simulating a skull base chordoma. In addition, treatments planned on CTs of the phantom with HU units modified were delivered to simulate systematic range uncertainties (range-error treatments). Finally, plans were delivered with the phantom rotated to simulate spatial errors. Results show excellent agreement between the calculated and the measured dose distribution: >99% and 98% of points with a gamma value <1 (3%/3 mm) for the 3D-IMPT and the DET plan, respectively. For both range and spatial errors, the 3D-IMPT plan was more robust than the DET plan. Both plans were more robust to range than to the spatial uncertainties. Finally, for range error treatments, measured distributions were compared to a model for predicting delivery errors in the treatment planning system. Good agreement has been found between the model and the measurements for both types of IMPT plan.

The 'worst case scenario' (also known as the minimax approach in optimization terms) is a common approach to model the effect of delivery uncertainties in proton treatment planning. Using the 'dose-error-bar distribution' previously reported by our group as an example, we have investigated in more detail one of the underlying assumptions of this method. That is, the dose distributions calculated for a limited number of worst case patient positioning scenarios (i.e. limited number of shifts sampled on a spherical surface) represent the worst dose distributions that can occur during the patient treatment under setup uncertainties. By uniformly sampling patient shifts from anywhere within a spherical error-space, a number of treatment scenarios have been simulated and dose deviations from the nominal dose distribution have been computed. The dose errors from these simulations (comprehensive approach) have then been compared to the dose-error-bar approach previously reported (surface approximation) using both point-by-point and dose- and error-volume-histogram analysis (DVH/EVHs). This comparison has been performed for two different clinical cases treated using intensity modulated proton therapy (IMPT): a skull-base and a spinal-axis tumor. Point-by-point evaluation shows that the surface approximation leads to a correct estimation (95% accuracy) of the potential dose errors for the 96% and 85% of the irradiated voxels, for the two investigated cases respectively. We also found that the voxels for which the surface approximation fails are generally localized close to sharp soft tissue-bone interfaces and air cavities. Moreover, analysis of EVHs and DVHs for the two cases shows that the percentage of voxels of a given volume of interest potentially affected by a certain maximum dose error is correctly estimated using the surface approximation and that this approach also accurately predicts the upper and lower bounds of the DVH curves that can occur under positioning uncertainties. In conclusion, the assumption that the larger the patient shift the worse the dose error does not always hold on a point-by-point basis. Nevertheless, when performing a volumetric analysis, a limited set of worst case error scenarios correctly represents the worst quality of the plan in presence of setup errors. As a consequence of these results, we believe that the worst case scenario approach can be used in the IMPT planning procedure for estimating plan robustness provided that the possible limitations of this approach are known.